The role of the novel adipocyte-derived protein adiponectin in human disease: An update

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 9, 2010, Pages 856-869

  Díez, Juan J ^a   Iglesias, P ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Adiponectin; Cardiovasacular disease; Diabetes; Hyperlipidemia; Mortality

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER;

ADIPOCYTE; BLOOD; CARDIOVASCULAR DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY;

ADIPOCYTES; ADIPONECTIN; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASES;

EID: 77956597116     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710791608325     Document Type: Article

References (199)

1. Scherer, P.E.; Williams, S.; Fogliano, M.; Baldini, G.; Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem., 1995, 270, 26746-26749.
2. Maeda, K.; Okubo, K.; Shimomura, I.; Funahashi, T.; Matsuzawa, Y.; Matsubara, K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem. Biophys. Res. Commun., 1996, 221, 286-289.
3. Hu, E.; Liang, P.; Spiegelman, B.M. AdipoQ is a novel adipocyte-specific gene dysregulated in obesity. J. Biol. Chem., 1996, 271 10697-10703.
4. Nakano, Y.; Tobe, T.; Choi-Miura, N.H; Mazda, T.; Tomita, T. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem. (Tokyo), 1996, 120, 803-812.
5. Wang, Y.; Lam, K.S.; Yau, M.H.; Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem. J., 2008, 409, 623-633
6. Fruebis, J.; Tsao, T.S.; Javorschi, S.; Ebbets-Reed, D.; Erickson, M.R.; Yen, F.T.; Bihain, B.E.; Lodish HF. Proteolitic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice Proc. Natl. Acad. Sci. USA, 2001, 98, 2005-2010.
7. Díez, J.J.; Iglesias, P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol., 2003, 148, 293-300.
8. Kubota, N.; Terauchi, Y.; Yamauchi, T.; Kubota, T.; Moroi, M.; Matsui, J.; Eto, K.; Yamashita, T.; Kamon, J.; Satoh, H.; Yano, W.; Froguel, P.; Nagai, R.; Kimura, S.; Kadowaki, T.; Noda, T. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem., 2002, 277, 25863-25866.
9. Maeda, N.; Shimomura, I.; Kishida, K.; Nishizawa, H.; Matsuda, M.; Nagaretani, H.; Furuyama, N.; Kondo, H.; Takahashi, M.; Arita, Y.; Komuro, R.; Ouchi, N.; Kihara, S.; Tochino, Y.; Okutomi, K.; Horie, M.; Takeda, S.; Aoyama, T.; Funahashi, T.; Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med., 2002, 8, 731-737.
10. Matsuda, M.; Shimomura, I.; Sata, M.; Arita, Y.; Nishida, M.; Maeda, N., Kumada, M.; Okamoto, Y.; Nagaretani, H.; Nishizawa, H.; Kishida, K.; Komuro, R.; Ouchi, N.; Kihara, S.; Nagai, R.; Funahashi, T.; Matsuzawa, Y. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J. Biol. Chem., 2002, 277, 37487-34491.
11. Berg, A.H.; Combs, T.P.; Du, X.; Brownlee, M.; Scherer, P. The adipocite-secreted protein ACRP30 enhances hepatic insulin action. Nat. Med., 2001, 7, 947-953.
12. Yamauchi, T.; Kamon, J.; Waki, H.; Terauchi, Y.; Kubota, N.; Hara, K.; Mori, Y.; Ide, T.; Murakami, K.; Tsuboyama-Kasaoka, N.; Ezaki, O.; Akanuma, Y.; Gavrilova, O.; Vinson, C.; Reitman, M.L.; Kagechika, H.; Shudo, K.; Yoda, M.; Nakano, Y.; Tobe, K.; Nagai, R.; Kimura, S.; Tomita, M.; Froguel, P.; Kadowaki, T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med., 2001, 7, 941946.
13. Kato, H.; Kashiwagi, H.; Shiraga, M.; Tadokoro, S.; Kamae, T.; Ujiie, H.; Honda, S., Miyata, S.; Ijiri, Y.; Yamamoto, J.; Maeda, N.; Funahashi, T.; Kurata, Y.; Shimomura, I.; Tomiyama, Y.; Kanakura Y. Adiponectin acts as an endogenous antithrombotic factor Arterioscler. Thromb. Vasc. Biol., 2006, 26, 224-230.
14. Yamauchi, T.; Kamon, J.; Ito, Y.; Tsuchida, A.; Yokomizo, T.; Kita, S.; Sugiyama, T.; Miyagishi, M.; Hara, K.; Tsunoda, M.; Murakami, K.; Ohteki, T.; Uchida, S.; Takekawa, S.; Waki, H.; Tsuno, N.H.; Shibata, Y.; Terauchi, Y.; Froguel, P.; Tobe, K.; Koyasu, S.; Taira, K.; Kitamura, T.; Shimizu, T.; Nagai, R.; Kadowaki T. Adiponectin acts as an endogenous antithrombotic factor. Nature, 2003, 423, 762-769.
15. Kadowaki, T.; Yamauchi, T.; Kubota, N.; Hara, K.; Ueki, K.; Tobe, K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest., 2006, 116, 1784-1792.
16. Bjursell, M.; Ahnmark, A.; Bohlooly-Y, M.; Williamg-Olsson, L.; Rhedin, M.; Peng, X.R.; Ploj, K.; Gerdin, A.K.; Arnerup, G.; Elmgren, A.; Berg, A.L.; Oscarsson, J.; Lindén, D. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes, 2007, 56, 583-593.
17. Kadowaki, T.; Yamauchi, T. Adiponectin and adiponectin receptors. Endocr. Rev., 2005, 26, 439-451.
18. Kim, J.Y.; van de Wall, E.; Laplante, M.; Azzara, A.; Trujillo, M.E.; Hofmann, S.M.; Schraw, T.; Durand, J.L.; Li, H.; Li, G.; Jelicks, L.A.; Mehler, M.F.; Hui, D.Y.; Deshaies, Y.; Shulman, G.I.; Schwartz, G.J.; Scherer, P.E. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest., 2007, 117, 2621-2637.
19. Chen, H.; Montagnani, M.; Funahashi, T.; Shimomura, I.; Quon, M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem., 2003, 278, 45021-45026.
20. Arita, Y.; Kihara, S.; Ouchi, N.; Takahashi, M.; Maeda, K.; Miyagawa, J.; Hotta, K.; Shimomura, I.; Nakamura, T.; Miyaoka, K.; Kuriyama, H.; Nishida, M.; Yamashita, S., Okubo, K.; Matsubara, K.; Muraguchi, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa Y. Paradoxical decrease of an adipocyte specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999, 257, 79-83.
21. Weyer, C.; Funahashi, T.; Tanaka, S.; Hotta, K.; Matsuzawa, Y.; Pratley, R.E.; Tataranni, P.A. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab., 2001, 86, 1930-1935.
22. Matsubara, M.; Maruoka, S.; Katayose, S. Inverse relationship between plasma adiponectin and leptin concentrations in normalweight and obese women. Eur. J. Endocrinol., 2002, 147, 173-180.
23. Cnop, M.; Havel, P.J.; Utzschneider, K.M.; Carr, D.B.; Sinha, M.K.; Boyko, E.J.; Retzlaff, B.M.; Knopp, R.H.; Brunzell, J.D.; Kahn, S.E. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 2003, 46, 459-469
24. Yamamoto, Y., Hirose, H.; Saito, I.; Tomita, M.; Taniyama, M.; Matsubara, K.; Okazaki, Y.; Ishii, T.; Nishikai, K.; Saruta, T. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin. Sci. (London), 2002, 103, 137-142.
25. Choi, K.M.; Lee, J.; Lee, K.W.; Seo, J.A.; Oh, J.H.; Kim, S.G.; Kim, N.H.; Choi, D.S.; Baik SH. Serum adiponectin concentrations predict the development of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin. Endocrinol. (Oxford), 2004, 61, 75-80.
26. Choi, K.M.; Lee, J.; Lee, K.W.; Seo, J.A.; Oh, J.H.; Kim, S.G., Kim, H.N.; Choi, D.S.; Baik SH. The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors. Eur. J. Endocrinol., 2004, 150, 715-718.
27. Cavusoglu, E.; Ruwende, C.; Chopra, V.; Yanamadala, S.; Eng, C.; Clark, L.T.; Pinsky, D.J.; Marmur, J.D. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur. Heart J., 2006, 27, 2300-2309.
28. Pilz, S.; Managge, H.; Wellnitz, B.; Seelhorst, U.; Winkelmann, B.R.; Tiran, B.; Boehm, B.O.; Marz W. Adiponectin and mortality in patients undergoing coronary angiography. J. Clin. Endocrinol. Metab., 2006, 91, 4277-4286.
29. Gavrila, A.; Chan, J.L.; Yiannakouris, N.; Kontogianni, M.; Miller, L.C.; Ordova, C.; Mantzoros, C.S. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J. Clin. Endocrinol. Metab., 2003, 88, 4823-4831.
30. Fernández-Real, J.M.; López-Bermejo, A.; Casamitjana, R.; Ricart, W. Novel interactions of adiponectin with the endocrine system and inflamatory parameters. J. Clin. Endocrinol. Metab., 2003, 88, 2714-2718.
31. Lawlor, D.A.; Davey Smith, G.; Ebrahim, S., Thompson, C.; Sattar, N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J. Clin. Endocrinol. Metab., 2005, 90, 5677-5683.
32. Hotta, K.; Funahashi, T.; Arita, Y.; Takahashi, M.; Matsuda, M.; Okamoto, Y.; Iwahashi, H.; Kuriyama, H.; Ouchi, N.; Maeda, K.; Nishida, M.; Kihara, S.; Sakai, N.; Nakajima, T.; Hasegawa, K.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Hanafusa, T.; Matsuzawa, Y. Plasma concentrations of a novel adiposespecific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 1595-1599.
33. Valsamakis, G.; McTernan, P.G.; Chetty, R.; Al Daghri, N.; Field, A.; Hanif, W.; Barnett, A.H.; Kumar, S. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adiponectin. Metabolism, 2004, 53, 430-434.
34. Kim, D.M.; Yoon, S.J.; Ahn, C.W.; Cha, B.S.; Lim, S.K.; Kim, K.R.; Lee, H.C.; Huh, K.B. Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. Diab. Res. Clin. Pract., 2004, 66(Suppl 1), S139-S144.
35. Yang, W.S.; Lee, W.J.; Funahashi, T.; Tanaka, S.; Matsuzawa, Y.; Chao, C.L.; Chen, C.L.; Tai, T.Y.; Chuang, L.M. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab., 2001, 86, 38153819.
36. Holdstock, C.; Engstrom, B.E.; Ohrvall, M.; Lind, L.; Sundbom, M.; Karlsson, F,A. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J. Clin. Endocrinol. Metab., 2003, 88, 3177-3183.
37. Bobbert, T.; Rochlitz, H.; Wegewitz, U.; Akpulat, S.; Mai, K.; Weickert, M.O.; Möhlig, M.; Pfeiffer, A.F.; Spranger, J. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes, 2005, 54, 2712-2719.
38. Yang, W.S.; Lee, W.J.; Funahashi, T.; Tanaka, S.; Matsuzawa, Y.; Chao, C.L.; Chen, C.L.; Tai, T.Y.; Chuang, L.M. Plasma adiponectin levels in overweight and obese Asians. Obes. Res., 2002, 10, 1104-1110.
39. Menzaghi, C.; Trischitta, V.; Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes, 2007, 56, 1198-1209.
40. Hivert, M.F.; Manning, A.K.; McAteer, J.B.; Florez, J.C.; Dupuis, J.; Fox, C.S.; O'Donnell, C.J.; Cupples, L.A.; Meigs, J.B. Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits: the Framingham Offspring Study. Diabetes, 2008, 57, 3353-3359.
41. Kishida, K.; Nagaretani, H.; Kondo, H.; Kobayashi, H.; Tanaka, S.; Maeda, N.; Nagasawa, A.; Hibuse, T.; Ohashi, K.; Kumada, M.; Nishizawa, H.; Okamoto, Y.; Ouchi, N.; Maeda, K.; Kihara, S.; Funahashi, T.; Matsuzawa, Y. Disturbed secretion of mutant adiponectin associated with the metabolic syndrome. Biochem. Biophys. Res. Commun., 2003, 306, 286-292.
42. Matsubara, M.; Katayose, S.; Maruoka, S. Decreased plasma adiponectin concentrations in nondiabetic women with elevated homeostasis model assessment ratios. Eur. J. Endocrinol., 2003, 148, 343-350.
43. Fernandez-Real, J.M.; Castro, A.; Vazquez, G.; Casamitjana, R.; Lopez-Bermejo, A.; Penarroja, G.; Ricart W. Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care, 2004, 27, 739-745.
44. Weiss, R.; Dufour, S.; Groszmann, A.; Petersen, K.; Dziura, J.; Taksali, S.E.; Shulman, G.; Caprio S. Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid acumulation. J. Clin. Endocrinol. Metab., 2003, 88, 2014-2018.
45. Stefan, N.; Vozarova, B.; Funahashi, T.; Matsuzawa, Y.; Weyer, C.; Lindsay, R.S.; Youngren, J.F.; Havel, P.J.; Pratley, R.E.; Bogardus, C.; Tataranni, P.A. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes, 2002, 51, 1884-1888.
46. Hara, K.; Horikoshi, M.; Yamauchi, T.; Yago, H.; Miyazaki, O.; Ebinuma, H.; Imai, Y.; Nagai, R.; Kadowaki T. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care, 2006, 29, 1357-1362.
47. Lindsay, R.S.; Funahashi, T.; Hanson, R.L.; Matsuzawa, Y.; Tanaka, S.; Tataranni, P.A.; Knowler, W.C.; Krakoff, J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet, 2002, 360, 57-58.
48. Daimon, M.; Oizumi, T.; Saitoh, T.; Kameda, W.; Hirata, A.; Yamaguchi, H.; Ohnuma, H.; Igarashi, M.; Tominaga, M.; Kato, T. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study. Diabetes Care, 2003, 26, 2015-2020.
49. Spranger, J.; Kroke, A.; Mohlig, M.; Bergmann, M.M.; Ristow, M.; Boeing, H.; Pfeiffer, A.F. Adiponectin and protection against type 2 diabetes mellitus. Lancet, 2003, 361, 226-228.
50. Yamamoto, Y.; Hirose, H.; Saito, I.; Nishikai, K.; Saruta T. Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J. Clin. Endocrinol. Metab., 2004, 89, 87-90.
51. Duncan, B.B.; Schmidt, M.I.; Pankow, J.S.; Bang, H.; Couper, D.; Ballantyne, C.M.; Hoogeveen, R.C.; Heiss G. Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes, 2004, 53, 2473-2478.
52. Koenig, W.; Khuseyinova, N.; Baumert, J.; Meisinger, C.; Löwel, H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middleaged men: results from the 18-year follow-up of a large cohort from southern Germany. J. Am. Coll. Cardiol., 2006, 48, 1369-1377.
53. Snijder, M.B.; Heine, R.J.; Seidell, J.C.; Bouter, L.M.; Stehouwer, C.D.; Nijpels, G.; Funahashi, T.; Matsuzawa, Y.; Shimomura, I.; Dekker, J.M. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn study. Diabetes Care, 2006, 29, 2498-2503.
54. Wannamethee, S.G.; Lowe, G.D.O.; Rumley, A.; Cherry, L.; Whincup, P.H.; Sattar, N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care, 2007, 30, 1200-1205.
55. Ley, S.H.; Harris, S.B.; Connelly, P.W.; Mamakeesick, M.; Gittelsohn, J.; Hegele, R.A.; Retnakaran, R.; Zinman, B.; Hanley, A.J. Adipokines and incident type 2 diabetes in an Aboriginal Canadian population: the Sandy Lake Health and Diabetes Project. Diabetes Care, 2008, 31, 1410-1415.
56. Mather, K.J.; Funahashi, T.; Matsuzawa, Y.; Edelstein, S.; Bray, G.A.; Kahn, S.E.; Crandall, J.; Marcovina, S.; Goldstein, B.; Goldberg, R.; Diabetes Prevention Program. Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program. Diabetes, 2008, 57, 980-986.
57. Li, S.; Shin, H.J.; Ding, E.L.; van Dam, R.M. Adiponectin levels and risk of type 2 diabetes. A systematic review and meta-analysis. JAMA, 2009, 302, 179-188.
58. Nakashima, R.; Kamei, N.; Yamane, K.; Nakanishi, S.; Nakashima, A.; Kohno, N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J. Clin. Endocrinol. Metab., 2006, 91, 3873-3877.
59. Heidemann, C.; Sun, Q.; van Dam, R.M.; Meigs, J.B.; Zhang, C.; Tworoger, S.S.; Mantzoros, C.S.; Hu. F.B. Total and highmolecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann. Intern. Med., 2008, 149, 307-316.
60. Nagasaka, S.; Taniguchi, A.; Aiso, Y.; Yatagai, T.; Nakamura, T.; Nakai, Y.; Fukushima, M.; Kuroe, A.; Ishibashi, S. Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes. Diabetes Care, 2003, 26, 2215-2216.
61. Lund, S.S.; Tarnow, L.; Stehouwer, C.D.; Schalkwijk, C.G.; Frandsen, M.; Smidt, U.M.; Pedersen, O.; Parving, H.H.; Vaag, A. Targeting hyperglycaemia with either metformin or repaglinide in nonobese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes Obes. Metab., 2007, 9, 394-407.
62. Phillips, S.A.; Ciaraldi, T.P.; Kong, A.P.; Bandukwala, R.; Aroda, V.; Carter, L.; Baxi, S., Mudaliar, S.R.; Henry, R.R. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes, 2003, 52, 667-674.
63. Maeda, N.; Takahashi, M.; Funahashi, T.; Kihara, S.; Nishizawa, H.; Kishida, K.; Nagaretani, H.; Matsuda, M.; Komuro, R.; Ouchi, N.; Kuriyama, H.; Hotta, K.; Nakamura, T.; Shimomura, I.; Matsuzawa, Y. PPAR ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes, 2001, 50, 2094-2099.
64. Yu, J.G.; Javorschi, S.; Hevener, A.L.; Kruszynska, Y.T.; Norman, R.A.; Sinha, M.; Olefsky, J.M. The effect of thiazolidinedione on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes, 2002, 51, 2968-2974.
65. Yang, W.S.; Jeng, C.Y.; Wu, T.J.; Tanaka, S.; Funahashi, T.; Matsuzawa, Y.; Wang, J.P.; Chen, C.L.; Tai, T.Y.; Chuang, L.M. Synthetic peroxisome proliferator-activated receptoragonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care, 2002, 25, 376-380.
66. Hirose, H.; Kawai, T.; Yamamoto, Y.; Taniyama, M.; Tomita, M.; Matsubara, K.; Okazaki, Y.; Ishii, T.; Oguma, Y.; Takei, I.; Saruta, T. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism, 2002, 51, 314-317
67. Bodles, A.M.; Banga, A.; Rasouli, N.; Ono, F., Kern, P.A.; Owens, R.J. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am. J. Physiol. Endocrinol. Metab., 2006, 291, E1100-E1105.
68. Qurashi, S.; Mynarcik, D.C.; McNurlan, A.A., Ahn, H.; Ferris, R.; Gelato, M.C. Importance of the high-molecular-mass isoform of adiponectin in improved insulin sensitivity with rosiglitazone treatment in HIV disease. Clin. Sci. (London), 2008, 115, 197-202.
69. Iwaki, M.; Matsuda, M.; Maeda, N.; Funahashi, T.; Matsuzasa, Y.; Makishima, M.; Shimomura, I. Induction of adiponectin, a fatderived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes, 2003, 52, 1655-1663.
70. Matsubara, M.; Maruoka, S.; Katayose, S. Decreased plasma adiponectin concentrations in women dith dyslipidemia. J. Clin. Endocrinol. Metab., 2002, 87, 2764-2769.
71. Zietz, B.; Herfarth, H.; Paul, G.; Ehling, A.; Muller-Ladner, U.; Scholmerich, J.; Schaffler, A. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett., 2003, 545, 103-104.
72. Von Eynatten, M.; Hamann, A.; Twardella, D.; Nawroth, P.P.; Brenner, H.; Rothenbacher, D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin. Che, 2006, 52, 853-859.
73. Gouni-Berthold, I.; Berthold, H.K.; Chamberland, J.P.; Krone, W.; Mantzoros, C.S. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin. Endocrinol. (Oxford), 2008, 68, 536-541.
74. Gannagé-Yared, M.H.; Azar, R.R.; Amm-Azar, M.; Khalifé, S.; Germanoa-Haddad, M.; Neemtallah, R.; Halaby, G. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism, 2005, 54, 947-951.
75. Arca, M.; Cambuli, V.M.; Montali, A.; Sentinelli, F.; Filippi, E.; Campagna, F.; Quagliarini, F.; Antonini, R.; Romeo, S.; Baroni, M,G. Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment. Nutr. Metab. Cardiovasc. Dis., 2009, 19, 660-666.
76. Inami, N.; Nomura, S.; Shouzu, A.; Omoto, S.; Kimura, Y.; Takahashi, N.; Tanaka, A.; Nanba, M.; Shouda, Y.; Iwasaka, T. Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol. Haemost. Thromb., 2007, 36, 1-8.
77. Nomura, S.; Inami, N., Shouzu, A.; Omoto, S.; Kimura, Y.; Takahashi, N.; Tanaka, A.; Urase, F.; Maeda, Y.; Ohtani, H.; Iwasaka, T. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets, 2009, 20, 16-22.
78. Qu, H.Y.; Xiao, Y.W.; Jiang, G.H., Wang, Z.Y.; Zhang, Y.; Zhang, M. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm. Res., 2009, 26, 958-964.
79. Oki, K.; Koide, J.; Nakanishi, S.; Nakashima, R.; Yamane, K. Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocr. J., 2007, 54, 431-435.
80. Otto, C.; Otto, B.; Frost, R.J.; Vogeser, M.; Pfeiffer, A.F.; Spranger, J.; Parhofer, K.G. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol., 2007, 44, 65-68.
81. Rosenson, R.S. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity, 2009, 17, 504-509.
82. Plaisance, E.P.; Grandjean, P.W.; Brunson, B.L.; Judd, R.L. Increased total and high-molecular weight adiponectin after extended-release niacin. Metabolism, 2008, 57, 404-409.
83. Von Eynatten, M.; Schneider, J.G.; Humpert, P.M.; Rudofsky, G.; Schmidt, N.; Barosch, P.; Hamann, A.; Morcos, M.; Kreuzer, J.; Bierhaus, A.; Nawroth, P.P.; Dugi, K.A. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care, 2004, 27, 2925-2929.
84. Schneider, J.G.; von Eynatten, M.; Schiekofer, S.; Nawroth, P.P.; Dugi, K.A. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care, 2005, 28, 2181-2186.
85. Adamczak, M.; Wiecek, A.; Funahashi, T.; Chudek, J.; Kokot, F.; Matsuzawa, Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am. J. Hypertens., 2003, 16, 7275.
86. Furuhashi, M.; Ura, N.; Higashiura, K.; Murakami, H.; Tanaka, M.; Moniwa, N.; Yoshida, D.; Shimamoto, K. Blockade of the reninangiotensin system increases adiponectin concentration in patients with essential hypertension. Hypertension, 2003, 42, 76-81.
87. Kazumi, T.; Kawaguchi, A.; Sakai, K.; Hirano, T.; Yoshino, G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care, 2002, 25, 971-976.
88. Mallamaci, F.; Zoccali, C.; Cuzzola, F.; Tripepi, G.; Cutrupi, S.; Parlongo, S.; Tanaka, S.; Ouchi, N.; Kihara, S.; Funahashi, T.; Matsuzawa Y. Adiponectin in essential hypertension. J. Nephrol., 2002, 15, 507-511.
89. Iwashima, Y.; Katsuya, T.; Ishikawa, K.; Ouchi, N.; Ohishi, M.; Sugimoto, K.; Fu, Y.; Motone, M.; Yamamoto, K.; Matsuo, A.; Ohashi, K.; Kihara, S.; Funahashi, T.; Rakugi, H.; Matsuzawa, Y.; Ogihara T. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension, 2004, 43, 1318-1323.
90. Chow, W.S.; Cheung, B.M.; Tso, A.W.; Xu, A., Wat, N.M.; Fong, C.H.; Ong, L.H.; Tam, S.; Tan, K.C.; Janus, E.D.; Lam, T.H.; Lam, K.S. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension, 2007, 49, 1455-1461.
91. Yilmaz, M.I.; Sonmez, A.; Caglar, K.; Celik, T.; Yenicesu, M.; Eyileten, T.; Acikel, C.; Oguz, Y.; Yavuz, I.; Vural, A. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology, 2007, 12, 147-153.
92. Benndorf, R.A.; Rudolf, T.; Appel, D.; Schwedhelm, E.; Maas, R.; Schulze, F.; Siberhorn, E.; Böger, R.H. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism, 2006, 55, 1159-1164.
93. Koh, K.K.; Han, S.H.; Ahn, J.Y.; Chung, W.J.; Lee, Y.; Shin, E.K. Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int. J. Cardiol., 2009, 133, 23-31.
94. Furuya, R.; Odamaki, M.; Kumagai, H.; Hishida, A. Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients. Blood Purif., 2006, 24, 445-450.
95. Koh, K.K.; Quon, M.J.; Han, S.H.; Chung, W.J.; Lee, Y.; Shin, E,K. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int. J. Cardiol., 2006, 108, 96-100.
96. Delles, C.; Raff, U.; Mimran, A.; Fauvel, J.P.; Ruilope, L.M.; Schmieder, R.E. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes. Am. J. Hypertens., 2008, 21, 1330-1336.
97. Nakamura, T.; Kawachi, K.; Saito, Y.; Saito, T.; Morishita, K.; Hoshino, J.; Hosoi, T.; Iwasaki, T.; Ohyama, Y.; Kurabayashi, M. Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int. Heart J., 2009, 50, 501-512.
98. Nomura, S.; Shouzu, A.; Omoto, S.; Nishikawa, M.; Fukuhara, S.; Iwasaka, T. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb. Res., 2006, 117, 385-392.
99. Usui, I.; Fujisaka, S.; Yamazaki, K.; Takano, A.; Murakami, S.; Yamazaki, Y.; Urakaze, M.; Hachiya, H.; Takata, M.; Senda, S.; Iwata, M.; Satoh, A.; Sasaoka, T.; Ak, N.D.; Temaru, R.; Kobayashi, M. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diab. Res. Clin. Pract., 2007, 77, 210-214.
100. Aksnes, T.A.; Seljeflot, I., Torjesen, P.A.; Höieggen, A.; Moan, A.; Kjeldsen, S.E. Improved insulin sensitivity by the angiotensin IIreceptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. Metabolism, 2007, 56, 1470-1477.
101. Guo, L.L.; Pan, Y.; Jin, H.M. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol. Dial. Transplant., 2009, 24, 1876-1883.
102. Stenvinkel, P., Marchlewska, A.; Pecoits-Filho, R.; Heimburger, O.; Zhang, Z.; Hoff, C.; Holmes, C.; Axelsson, J.; Arvidsson, S.; Schalling, M.; Barany, P.; Lindholm, B.; Nordfors, L. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int., 2004, 65, 274-281.
103. Becker, B.; Kronenberg, F.; Kielstein, J.T.; Haller, H.; Morath, C.; Ritz, E.; Fliser, D. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J. Am. Soc. Nephrol., 2005, 16, 1091-1098.
104. Tan, K.C.; Xu, A.; Chow, W.S., Lam, M.C.; Ai, V.H.; Tam, S.C.; Lam, K,S. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J. Clin. Endocrinol. Metab., 2004, 89, 765-769.
105. Looker, H.C.; Krakoff, J., Funahashi, T.; Matsuzawa, Y.; Tanaka, S.; Nelson, R.G.; Knowler, W.C.; Lindsay, R.S.; Hanson, R.L. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J. Clin. Endocrinol. Metab., 2004, 89, 4010-4017.
106. Hadjadj, S.; Aubert, R.; Fumeron, F.; Pean, F.; Tichet, J.; Roussel, R.; Marre, M. Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. Diabetologia, 2005, 48, 1088-1092.
107. Frystyk, J.; Tarnow, L.; Krarup, H.T.; Parving, H.H.; Flyvbjerg, A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia, 2005, 48, 1911-1918.
108. Saraheimo, M.; Forsblom, C.; Fagerudd, J.; Teppo, A.M.; Pettersson-Fernholm, K.; Frystyk, J.; Flyvbjerg, A.; Groop, P.H.; FinnDiane study group. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care, 2005, 28, 1410-1414.
109. Schalkwijk, C.G.; Chaturvedi, N.; Schram, M.T.; Fuller, J.H.; Stehouwer, C.D.A.; EURODIAB Prospective Complications Study Group. Adiponectin is inversely associated with renal function in type 1 diabetic patients. J. Clin. Endocrinol. Metab., 2006, 91, 129-135.
110. Zoccali, C.; Mallamaci, F.; Tripepi, G.; Benedetto, F.A.; Cutrupi, S.; Parlongo, S.; Malatino, L.S.; Bonanno, G.; Seminara, G., Rapisarda, F.; Fatuzzo, P.; Buemi, M.; Nicocia, G.; Tanaka, S.; Ouchi, N.; Kihara, S.; Funahashi, T.; Matsuzawa, Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J. Am. Soc. Nephrol., 2002, 13, 134-141
111. Díez, J.J.; Iglesias, P.; Fernández-Reyes, M.J.; Aguilera, A.; Bajo, M.A.; Alvarez-Fidalgo, P.; Codoceo, R.; Selgas R. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin. Endocrinol. (Oxford), 2005, 62, 242-249.
112. Chudek, J.; Adamczak, M.; Karkoszka, H.; Budzi ski, G.; Ignacy, W.; Funahashi, T.; Matsuzawa, Y.; Cierpka, L.; Kokot, F.; Wiecek A. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant. Proc., 2003, 35, 2186-2189
113. Kato, K.; Osawa, H.; Ochi, M.; Kusunoki, Y.; Ebisui, O.; Ohno, K.; Ohashi, J.; Shimizu, I.; Fujii, Y.; Tanimoto, M.; Makino, H. Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy. Clin. Endocrinol. (Oxford), 2008, 68, 442-449.
114. Zoccali, C.; Mallamaci, F.; Panuccio, V.; Tripepi, G.; Cutrupi, S.; Parlongo, S.; Catalano, F.; Tanaka, S.; Ouchi, N.; Kihara, S.; Funahashi, T.; Matsuzawa, Y. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int., 2003, 63 (Suppl 84), S98-S102.
115. Yilmaz, M.I.; Saglam, M.; Qureshi, A.R.; Carrero, J.J.; Caglar, K.; Eyileten, T.; Sonmez, A.; Cakir, E.; Oguz, Y.; Vural, A.; Yenicesu, M.; Stenvinkel, P.; Lindholm, B.; Axelsson J. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol. Dial. Transplant., 2008, 23, 1621-1627.
116. Sharma, K.; RamachandraRao, S.; Qiu, G.; Usui, H.K.; Zhu, Y.; Dunn, S.R.; Quedraogo, R.; Hough, K.; McCue; Chan, L.; Falkner, B.; Goldstein, B.J. Adiponectin regulates albuminuria and podocyte function in mice. J. Clin. Invest., 2008, 118, 1645-1656.
117. Tentolouris, N.; Doulgerakis, D.; Moyssakis, I.; Kyriaki, D.; Makrilakis, K.; Kosmadakis, G.; Stamatiadis, D.; Katsilambros, N.; Stathakis, C. Plasma adiponectin concentrations in patients with chronic renal failure: relationship with metabolic risk factors and ischemic heart disease. Horm. Metab. Res., 2004, 36, 721-727.
118. Yu, Z.Z.; Ni, Z.H.; Gu, L.Y.; Lin, A.W.; Fang, W.; Yao, Q.; Lindholm, B.; Qian, J.Q. Adiponectin is related to carotid artery plaque and a predictor of cardiovascular outcome in a cohort of nondiabetic peritoneal dialysis patients. Blood Purif., 2008, 26, 386-393.
119. Pilz, S.; Horejsi, P.; Möller, R.; Almer, G.; Scharnagl, H.; Stojakovic, T.; Dimitrova, R.; Weihrauch, G.; Borkenstein, M.; Maerz, W.; Schauenstein, K.; Mangge, H. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J. Clin. Endocrinol. Metab., 2005, 90, 4792-4796.
120. Shimabukuro, M.; Higa, N.; Asahi, T.; Oshiro, Y.; Takasu, N.; Tagawa, T.; Ueda, S.; Shimomura, I.; Funahashi, T.; Matsuzawa, Y. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J. Clin. Endocrinol. Metab., 2003, 88, 3236-3240.
121. Ouchi, N., Ohishi, M., Kihara, S.; Funahashi, T.; Nakamura, T.; Nagaretani, H.; Kumada, M.; Ohashi, K.; Okamoto, Y.; Nishizawa, H.; Kishida, K.; Maeda, N.; Nagasawa, A.; Kobayashi, H.; Hiraoka, K.; Komai, N.; Kaibe, M.; Rakugi, H.; Ogihara, T.; Matsuzawa Y. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension, 2003, 42, 231-234.
122. Ouchi, N.; Kihara, S.; Arita, Y.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Hotta, K.; Nishida, M.; Takahashi, M.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 1999, 100, 2473-2476.
123. Kojima, S.; Funahashi, T.; Sakamoto, T.; Miyamoto, S.; Soejima, H.; Hokamaki, J.; Kajiwara, I.; Sugiyama, S.; Yoshimura, M.; Fujimoto, K.; Miyao, Y.; Suefuji, H.; Kitagawa, A.; Ouchi, N.; Kihara, S.; Matsuzawa, Y; Ogawa, H. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart, 2003, 89, 667.
124. Kumada, M.; Kihara, S.; Sumitsuji, S.; Kawamoto, T.; Matsumoto, S.; Ouchi, N.; Arita, Y.; Okamoto, Y.; Shimomura, I.; Hiraoka, H.; Nakamura, T.; Funahashi, T.; Matsuzawa, Y.; Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 85-89.
125. Aso, Y.; Yamamoto, R.; Wakabayashi, S.; Uchida, T.; Takayanagi, K.; Takebayashi, K.; Okuno, T.; Inoue, T.; Node, K.; Tobe, T.; Inuki, T.; Nakano, Y. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes, 2006, 55, 1954-1960.
126. Nakamura, Y.; Shimada, K.; Fukuda, D.; Shimada, Y.; Ehara, S.; Hirose, M.; Kataoka, T.; Kamimori, K.; Shimodozono, S.; Kobayashi, Y.; Yoshiyama, M.; Takeuchi, K.; Yoshikawa, J. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart, 2004, 90, 528-533.
127. Rothenbacher, D.; Brenner, H.; März, W.; Koenig, W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur. Heart J., 2005, 26, 1640-1646.
128. Laughlin, G.A.; Barrett-Connor, E.; May, S.; Langenberg, C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am. J. Epidemiol., 2007, 165, 164-174.
129. Pischon, T.; Girman, C.J.; Hotamisligil, G.S.; Rifai, N.; Hu, F.B.; Rimm, E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA, 2004, 291, 1730-1737.
130. Costacou, T.; Zgibor, J.C.; Evans, R.W.; Otvos, J.; Lopes-Virella, M.F.; Tracy, R.P.; Orchard, T.J. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh epidemiology of diabetes complications study. Diabetologia, 2005, 48, 41-48.
131. Frystyk, J.; Berne, C.; Berglund, L.; Jensevik, K.; Flyvbjerg, A.; Zethelius, B. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J. Clin. Endocrinol. Metab., 2007, 92, 571-576.
132. Kojima, S.; Funahashi, T.; Otsuka, F.; Maruyoshi, H.; Yamashita, T.; Kajiwara, I.; Shimomura, H.; Miyao, Y.; Fujimoto, K.; Sugiyama, S.; Sakamoto, T.; Yoshimura, M.; Ogawa, H. Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction. Atherosclerosis, 2007, 194, 204-213.
133. Lim, S.; Koo, B.K.; Cho, S.W.; Kihara, S.; Funahashi, T.; Cho, Y.M.; Kim, S.Y.; Lee, H.K.; Shimomura, I.; Park, K.S. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean Atherosclerosis Study (KAS): a 42-month prospective study. Atherosclerosis, 2008, 196, 398-404.
134. Shioji, K.; Moriwaki, S.; Takeuchi, Y.; Uegaito, T.; Mutsuo, S.; Matsuda, M. Relationship of serum adiponectin level to adverse cardiovascular events in patients who undergo percutaneous coronary intervention. Circ. J., 2007, 71, 675-680.
135. Maahs, D.M.; Ogden, L.G., Kinney, G.L.; Wadwa, P., SnellBergeon, J.K.; Dabelea, D.; Hokanson, J.E.; Ehrlich, J.; Eckel, R.H.; Rewers, M. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation, 2005, 111, 747-753
136. Lindsay, R.S.; Resnick, H.E.; Zhu, J.; Tun, M.L.; Howard, B.V.; Zhang, Y.; Yeh, J.; Best, L.G. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 15-16.
137. Soderberg, S.; Colquhoun, D.; Keech, A.; Yallop, J.; Barnes, E.H.; Pollicino, C.; Simes, J.; Tonkin, A.M.; Nestel, P.; LIPID Study Investigators. Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the lipid study. Int. J. Obes. (London), 2009, 33, 123-130.
138. Schnabel, R.; Messow, C.M.; Lubos, E.; Espinola-Klein, C.; Rupprecht, H.J.; Bickel, C.; Sinning, C.; Tzikas, S.; Keller, T.; GenthZotz, S.; Lackner, K.J.; Münzel, T.F.; Blankenberg, S. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur. Heart J., 2008, 29, 649-657.
139. Sattar, N.; Wannamethee, G.; Sarwar, N.; Tchernova, J.; Cherry, L.; Wallace, A.M.; Danesh, J.; Whincut, P.H. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation, 2006, 114, 623-629.
140. Inoue, T.; Kotooka, N.; Morooka, T.; Komoda, H.; Uchida, T.; Aso, Y.; Inukai, T.; Okuno, T.; Node, K. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am. J. Cardiol., 2007, 100, 569-574.
141. von Eynatten, M.; Hamann, A.; Twardella, D.; Nawroth, P.P.; Brenner, H.; Rothenbacher, D. Atherogenic dyslipidaemia but not totaland high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur. Heart J., 2008, 29, 1307-1315.
142. Rizza, S.; Clementi, F.; Porzio, O.; Cardellini, M.; Savo, A.; Serino, M.; Chiricolo, G.; Romeo, F.; Lauro, R.; Federici, M. Adiponectin isoforms are not associated with the severity of coronary atherosclerosis but with undiagnosed diabetes in patients affected by stable CAD. Nutr. Metab. Cardiovasc. Dis., 2009, 19, 54-60.
143. Sattar, N.; Watt, P.; Cherry, L.; Ebrahim, S.; Davey Smith, G.; Lawlor, D.A. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study. J. Clin. Endocrinol. Metab., 2008, 93, 1846-1849.
144. Krzyzanowska, K.; Aso, Y.; Mittermayer, F.; Inukai, T.; Brix, J.; Schernthaner, G. High-molecular weight adiponectin does not predict cardiovascular events in patients with type 2 diabetes. Transl. Res., 2009, 153, 199-203.
145. Tamura, T.; Furukawa, Y.; Taniguchi, R.; Sato, Y.; Ono, K.; Horiuchi, H.; Nakagawa, Y.; Kita, T.; Kimura. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ. J., 2007, 71, 623-630.
146. McEntegart, M.B.; Awede, B.; Petrie, M.C.; Sattar, N.; Dunn, F.G.; MacFarlane, N.G.; McMurray, J.J. Increase in serum adiponectin concentration in patiens with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J., 2007, 28, 829-835.
147. Nakamura, T.; Funayama, H.; Kubo, N.; Yasu, Y.; Kawakami, M.; Saito, M.; Momomura, S.; Ishikawa, S.E. Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure. Circ. J., 2006, 70, 1557-1562.
148. Kistorp, C.; Faber, J.; Galatius, S.; Gustafsson, F.; Frystyk, J.; Flyvbjerg, A.; Hildebrandt, P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation, 2005, 112, 1756-1762.
149. George, J.; Patal, S.; Wexler, D.; Sharabi, Y.; Peleg, E.; Kamari, Y.; Grossman, E.; Sheps, D.; Keren, G.; Roth, A. Circulating adiponectin concentrations in patients with congestive heart failure. Heart, 2006, 92, 1420-1424.
150. Haugen, E.; Furukawa, Y.; Isic, A.; Fu, M. Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: a hospital cohort study. Int. J. Cardiol., 2008, 125, 216-219.
151. Komaba, H.; Igaki, N.; Goto, S.; Yokota, K.; Takemoto, T.; Hirosue, Y.; Goto, T. Adiponectin is associated with brain natriuretic peptide and left ventricular hypertrophy in hemodialysis patients with type 2 diabetes mellitus. Nephron Clin. Pract., 2007, 107, c103-c108.
152. Tsutamoto, T.; Tanaka, T.; Sakai, H.; Ishikawa, C.; Fujii, M.; Yamamoto, T.; Horie, M. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur. Heart J., 2007, 28, 1723-1730.
153. Dieplinger, B.; Poelz, W.; Haltmayer, M.; Mueller, T. Association of adiponectin and amino terminal proBNP in peripheral arterial disease. Clin. Chim. Acta, 2007, 377, 192-197.
154. Ang, D.S.; Welsh, P.; Watt, P.; Nelson, S.M.; Struthers, A.; Saltar, N. Serial changes in adiponectin and BNP in ACS patients: paradoxical associations with each other and with prognosis. Clin. Sci. (London), 2009, 117, 41-48.
155. Dieplinger, B.; Gegenhuber, A.; Poelz, W.; Haltmayer, M.; Mueller, T. Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure. Clin. Biochem., 2009, 42, 1190-1193.
156. Dieplinger, B.; Haltmayer, M.; Poelz; Mueller, T. Value of adiponectin as predictor of 5-year all-cause mortality in patients with symptomatic peripheral arterial disease: results from the Linz Peripheral Arterial Disease (LIPAD) study. Clin. Chim. Acta, 2009, 408, 87-91.
157. Iwashima, Y.; Horio, T.; Suzuki, Y.; Kihara, S.; Rakugi, H.; Kangawa, K.; Funahashi, T.; Ogihara, T.; Kawano, Y. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis, 2006, 188, 384-390.
158. Golledge, J.; Leicht, A.; Crowther, R.G.; Clancy, P.; Spinks, W.L.; Quigley, F. Association of obesity and metabolic syndrome with the severity and outcome of intermittent claudication. J. Vasc. Surg., 2007, 45, 40-46.
159. Lim, P.S.; Hu, C.Y.; Wu, M.Y.; Wu, T.K.; Chang, H.C. Plasma adiponectin is associated with ankle-brachial index in patients on haemodialysis. Nephrology, 2007, 12, 546-552.
160. Yamauchi, T.; Kamon, J.; Minokoshi, Y.; Ito, Y.; Waki, H.; Uchida, S.; Yamashita, S., Noda, M.; Kita, S.; Ueki, K.; Eto, K.; Akanuma, Y., Froguel, P.; Foufelle, F.; Ferre, P.; Carling, D.; Kimura, S.; Nagai, R.; Kahn, B.B.; Kadowaki, T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med., 2002, 8, 1288-1295.
161. Wu, X.; Motoshima, H.; Mahadev, K.; Stalker, T.J.; Scalia, R.; Goldstein, B.J. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes, 2003, 52, 1355-1363.
162. Yokota, T.; Oritani, K.; Takahashi, I.; Ishikawa, J.; Matsuyama, A.; Ouchi, N.; Kihara, S.; Funahashi, T.; Tenner, A.J.; Tomiyama, Y.; Matsuzawa, Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 2000, 96, 1723-1732.
163. Ouchi, N.; Kihara, S.; Arita, Y.; Nishida, M.; Matsuyama, A.; Okamoto, Y.; Ishigami, M.; Kuriyama, H.; Kishida, K.; Nishizawa, H.; Hotta, K.; Muraguchi, M.; Ohmoto, Y.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation, 2001, 103, 1057-1063.
164. Ouchi, N.; Kihara, S.; Arita, Y.; Okamoto, Y.; Maeda, K.; Kuriyama, H.; Hotta, K.; Nishida, M.; Takahashi, M.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through cAMP-dependent pathway. Circulation, 2000, 102, 1296-1301.
165. Arita, Y.; Kihara, S.; Ouchi, N.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Kumada, M.; Hotta, K.; Nishida, M.; Takahashi, M.; Nakamura, T.; Shimomura, I.; Muraguchi, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa, Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation, 2002, 105, 2893-2898.
166. Shibata, R.; Ouchi, N.; Ito, M.; Kihara, S.; Shiojima, I.; Pimentel, D.R.; Kumada, M.; Sato, K.; Schiekofer, S.; Ohashi, K.; Funahashi, T.; Colucci, W.S.; Walsh, K. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med., 2004, 10, 1384-1389.
167. Ishikawa, Y.; Akasaka, Y.; Ishii, T.; Yoda-Murakami, M.; ChoiMiura, N.H.; Tomita, M.; Ito, K.; Zhang, L.; Akishima, Y.; Ishihara, M.; Muramatsu, M.; Taniyama, M. Changes in the distribution pattern of gelatin-binding protein of 28 kDa (adiponectin) in myocardial remodeling after ischaemic injury. Histopathology, 2003, 42, 43-52.
168. Okamoto, Y.; Kihara, S.; Ouchi, N.; Nishida, M.; Arita, Y.; Kumada, M.; Ohashi, K.; Sakai, N.; Shimomura, I.; Kobayashi, H.; Terasaka, N.; Inaba, T.; Funahashi, T.; Matsuzawa Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2002, 106, 2767-2770.
169. Motoshima, H.; Wu, X.; Mahadev, K.; Goldstein, BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem. Biophys. Res. Commun. 2004, 315, 264-271.
170. Ouchi, N.; Kobayashi, H.; Kihara, S.; Kumada, M.; Sato, K.; Inonue, T.; Funahashi, T.; Walsh, K. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J. Biol. Chem., 2004, 279, 1304-1309.
171. Goldstein, B.J.; Scalia, R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J. Clin. Endocrinol. Metab., 2004, 89, 2563-2568.
172. Wannamethee, S.G.; Whincup, P.H.; Lennon, L.; Sattar, N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch. Intern. Med., 2007, 167, 1510-1517.
173. Maiolino, G.; Cesari, M.; Sticchi, D.; Zanchetta, M.; Pedon, L.; Antezza, K.; Pessina, A.C.; Rossi, G.P. Plasma adiponectin for prediction of cardiovascular events and mortality in high-risk patients. J. Clin. Endocrinol. Metab., 2008, 93, 3333-3340.
174. Chen, M.P.; Tsai, J.C.; Chung, F.M.; Yang, S.S.; Hsing, L.L., Shin, S.J., Lee, Y.J. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 821-826.
175. Efstathiou, S.P.; Tsioulos, D.I.; Tsiakou, A.G.; Gratsias, Y.E.; Pefanis, A.V.; Mountokalakis, T.D. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke, 2005, 36, 1915-1919.
176. Soderberg, S.; Stegmayr, B.; Stenlund, H.; Sjostrom, L.G.; Agren, A.; Johansson, L.; Weinehall, L.; Olsson T. Leptin, but not adiponectin, predicts stroke in males. J. Intern. Med., 2004, 256, 128-136.
177. Matsumoto, M.; Ishikawa, S.; Kajii, E. Association of adiponectin with cerebrovascular disease: a nested case-control study. Stroke, 2008, 39, 323-328.
178. Stot, D.J.; Welsh, P.; Rumley, A.; Robertson, M.; Ford, I.; Sattar, N.; Westendorp, R.G.; Jukema, J.W.; Cobbe, S.M.; Lowe, GD. Adipocytokines and risk of stroke in older people: a nested casecontrol study. Int. J. Epidemiol., 2009, 38, 253-261.
179. Komai, H.; Shibata, R.; Juri, M.; Matsushita, K.; Ouchi, N.; Murohara, T. Plasma adiponectin as a predictive factor of survival after a bypass operation for peripheral arterial disease. J. Vasc. Surg., 2009, 50, 95-99.
180. Matsumoto, M.; Ishikawa, S.; Kajii, E. Adiponectin and noncardiovascular death: a nested case-control study. Metabolism, 2008, 57, 811-818.
181. Menon, V.; Li, L.; Wang, X.; Greene, T.; Balakrishnan, V.; Madero, M.; Pereira, A.A.; Beck, G.J.; Kusek, J.W.; Collins, A.J.; Levey, A.S.; Sarnak, M.J. Adiponectin and mortality in patients with chronic kidney disease. J. Am. Soc. Nephrol., 2006, 17, 2599-2606.
182. Ohashi, N.; Kato, A.; Misaki, T.; Sakakima, M.; Fujigaki, Y.; Yamamoto, T.; Hishida, A. Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern. Med., 2008, 47, 485-491.
183. Ignacy, W.; Chudek, J.; Adamczak, M.; Funahashi, T.; Matsuzawa, Y.; Kokot, F.; Wiecek, A. Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease-a follow-up study. Nephron Clin. Pract., 2005, 101, c18-c24.
184. Jorsal, A.; Tarnow, L.; Frystyk, J.; Lajer, M.; Flyvbjerg, A.; Parving, H.H.; Vionnet, N.; Rossing, P. Serum adiponectin predicts allcause mortality and end stage renal disease in patients with type 1 diabetes and diabetic nephropathy. Kidney Int., 2008, 74, 649-654.
185. Rao, M.; Li, L.; Tighiouart, H.; Jaber, B.L.; Pereira, B.J.G.; Balakrishnan, V.S.; HEMO Study Group. Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol. Dial. Transplant., 2008, 23, 2619-2628.
186. Díez, J.J.; Estrada, P.; Bajo, M.A.; Fernández-Reyes, M.J.; Grande, C.; del Peso, G.; Heras, M.; Molina, A.; Iglesias, P.; SánchezVillanueva, R.; Selgas, R. High stable serum adiponectin levels are associated with a better outcome in prevalent dialysis patients. Am. J. Nephrol., 2009, 30, 244-252.
187. Drechsler, C.; Krane, V.; Winkler, K.; Dekker, F.W.; Wanner, C. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int., 2009, 76, 567-575.
188. Nakano, Y.; Tajima, S.; Yoshimi, A.; Akiyama, H.; Tsushima, M.; Tanioka, T.; Negoro, T.; Tomita, M.; Tobe, T. A novel enzymelinked immunosorbent assay specific for high-molecular-weight adiponectin. J. Lipid Res., 2006, 47, 1572-1582.
189. Dekker, J.M.; Funahashi, T.; Nijpels, G.; Pilz, S.; Stehouwer, C.D.; Snijder, M.B.; Bouter, L.M.; Matsuzawa, Y.; Shimomura, I.; Heine, R.J. Prognostic value of adiponectin for cardiovascular disease and mortality. J. Clin. Endocrinol. Metab., 2008, 93, 1489-1496.
190. Rathmann, W.; Herder, C. Adiponectin and cardiovascular mortality: evidence for "reverse epidemiology". Horm. Metab. Res., 2007, 39, 1-2.
191. Teoh, H.; Strauss, M.H.; Szmitko, P.E.; Verma, S. Adiponectin and myocardial infarction: a paradox or a paradigm? Eur. Heart J., 2006, 27, 2266-2268.
192. Kalantar-Zadeh, K.; Block, G.; Horwich, T.; Fonarow, G.C. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J. Am. Coll. Cardiol., 2004, 43, 1439-1444.
193. Kaysen, G.A. Association between inflammation and malnutrition as risk factors of cardiovascular disease. Blood Purif., 2006, 24, 51-55
194. Kopple, J.D. The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. Am. J. Clin. Nutr., 2005, 81, 1257-1266.
195. Wang, Y.; Xu, A.; Knight, C.; Xu, L.Y.; Cooper, G.J. Hydroxilation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J. Biol. Chem., 2002, 277, 19521-19529.
196. Kollertis, B.; Fliser, D.; Heid, I.M.; Ritz, E.; Kronenberg, F.; MMKD Study Group. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int., 2007, 71, 1279-1286.
197. Qi, T.; Takahashi, N.; Hileman, S.M.; Patel, H.R.; Berg, A.H.; Pajvani, U.B.; Sherer, P.; Ahima, S. Adiponectin acts in the brain to decrease body weight. Nat. Med., 2004, 10, 524-529.
198. Lara-Castro, C.; Luo, N.; Wallace, P.; Klein, R.L.; Garvey, W.T. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes, 2006, 55, 249-259.
199. Hattori, Y.; Hattori, S.; Akimoto, K.; Nishikimi, T.; Suzuki, K.; Matsuoka, H.; Kasai, K. Globular adiponectin activates nuclear factorand activating protein-1 and enhances angiotensin IIinduced proliferation in cardiac fibroblasts. Diabetes, 2007, 56, 804-808.